THURSDAY, Jan. 19 (HealthDay News) – Measuring levels of a key protein may predict the long-term risk of progressive loss of kidney function in people with mild to moderate kidney disease, researchers from Austria report.
“Patients with primary kidney disease would like to know if they are at risk for disease progression, which often results in renal replacement therapy such as hemodialysis and / or kidney transplantation,” co-author of the study, Dr Florian Kronenberg, of the Medical University of Innsbruck, said in a prepared statement.
“Our results show that [the protein] apoA-IV is an excellent predictor of the progression of kidney disease, adding important and additional information in addition to the exact determination of kidney function, ”said Kronenberg.
The study included 177 people with mild to moderate kidney disease who were followed for seven years. At the start of the study, their blood lipid levels were checked, including the levels of apolipoproteins, which carry lipids (including cholesterol) in the blood.
As reported in the February issue of Journal of the American Society of Nephrology, approximately 37 percent of study participants experienced decreased kidney function over the seven-year follow-up period. But for patients with elevated apoA-IV levels, the average time to kidney disease progression was 54 months, compared to 70 months for those with lower apoA-IV levels, according to the study.
The results suggest that measuring apoA-IV levels helps predict the long-term risk of progressive kidney disease in patients with kidney failure, regardless of other factors, such as the patient’s initial level of kidney function. .
“ApoA-IV is not only an early marker for kidney failure, but also predicts whether kidney function will worsen in the years to come,” Kronenberg said.
– Robert Preidt
SOURCE: American Society of Nephrology, press release, January 6, 2006
Copyright © 2006 ScoutNews LLC. All rights reserved.
KEEP SCROLLING FOR THE NEXT NEWS ARTICLE